PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ction. Act of 1005, no persons are required to respond to a collection of information upless it displays a valid OMB control.

& TRADES	Application Number	10/632,706
TRANSMITTAL	Filing Date	August 1, 2003
FORM	First Named Inventor	James D. Marks
used for all correspondence after initial filing)	Group Art Unit	1645
	Examiner Name	Virginia Allen Portner

(to be used for all correspondence after initial filing)		First Named inventor		Junes D. Marks	
		Group Art Unit		1645	
			Examiner Name	,	Virginia Allen Portner
	Total Number of Pages in This Submi	ssion	Attorney Docket Number	r	407T-895120US
_	· · · · · · · · · · · · · · · · · · ·	ENCLOS	CIIDES (about all that any	2/1/	
_			•	(עויג	
	Fee Transmittal Form	Assignm (for an A	nent Papers Application)		After Allowance Communication to Group
	Fee Attached	Drawing	(s)		Appeal Communication to Board of Appeals and Interferences
	Amendment / Response	Licensin	ng-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
	After Final	Petition and Acc	Routing Slip (PTO/SB/69)		Proprietary Information
	Affidavits/declaration(s)	Petition	to Convert to a nal Application		Status Letter
Extension of Time Request		Power o	f Attorney, Revocation of Correspondence	X	Additional Enclosure(s) (please identify below):
Express Abandonment Request		Termina	l Disclaimer		<b>2</b> Enclosed Reference receipt acknowledgment
X Information Disclosure Statement			ntity Statement t for Refund		postcard
	Certified Copy of Priority Document(s)	Authorization to	Charge Deposit Account	or any	y additional fees associated with
	Becomes to Missing Borto/	this paper or dur			, including any extensions of time
	Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks			
	SIGNATU	RE OF APPLI	CANT, ATTORNEY, OR A	AGE	NT
	Firm or Individual name  Tom Hunter, Re	eg. No. 38,498	, Quine Intellect	ual I	Property Law Group P.C.
	Signature Thy	M	_		
	Date October 7, 2005	5			
1		CERTIFICA	ATE OF MAILING		
	hereby certify that this correspondence is being facsimile trenvelope addressed to: Commissioner for Patents, P.O. Box				

CERTIFICATE OF MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USP envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA						
Typed or printed name Chianti Appling						
Signature Lapp	7 Date	10/7/05				

I hereby calculate that this correspondence is being deposited with the URAL Braies Postal Service first class mail in an envelope addressed to:

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450, on October 7, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

Chianti Appling

Attorney Docket No. 407T-895120US Client Ref. No. 1998-013-2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

James D. Marks, et al.

Application No.: 10/632,706

Filed: August 1, 2003

For: THERAPEUTIC MONOCLONAL

ANTIBODIES THAT NEUTRALIZE

BOTULINUM NEUROTOXINS

Confirmation No.

Examiner: Virginia Allen Portner

Art Unit: 1645

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of International Search Report for corresponding International Application No. PCT/US03/24371. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

James D. Marks, et al.

Application No.: 10/632,706

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Tom Hunter, J.D., Ph.D.

Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458 Alameda, CA 94501

(510) 337-7871

Fax (510) 337-7877

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known			
Application Number	10/632,706		
Filing Date	August 1, 2003_		
First Named Inventor	James D. Marks		
Group Art Unit	1645		
Examiner Name	Virgina Allen Portner		
Attorney Docket Number	407T-895120US		
Date Submitted	October 7, 2005		
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number		

	1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines,
Examiner Cite Initials No.	Number	Kind Code (if known)	Where Relevant Passages or Relevant Figures Appeal			
	1	2004/0265935 A1		Atassi	12/30/2004	
	2	2004/0175385 A1		Marks et al.	09/09/2004	

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document				Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
								T
				<del> </del>				$\vdash$
								igspace

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	3	HALL (2004) Journal of Immunological Methods 288, pp. 55-60	
	4	OSHIMA (1997) Molecular Immunology Vol. 34, No. 14, pp. 1031-1040	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.